KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vir Biotechnology (VIR) EBITDA (2018 - 2025)

Vir Biotechnology's EBITDA history spans 8 years, with the latest figure at -$47.9 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 59.09% to -$47.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$479.3 million, a 18.37% increase, with the full-year FY2025 number at -$479.3 million, up 18.37% from a year prior.
  • EBITDA hit -$47.9 million in Q4 2025 for Vir Biotechnology, up from -$173.4 million in the prior quarter.
  • Over the last five years, EBITDA for VIR hit a ceiling of $1.0 billion in Q1 2022 and a floor of -$231.3 million in Q3 2024.
  • Historically, EBITDA has averaged -$24.8 million across 5 years, with a median of -$139.3 million in 2023.
  • The widest YoY moves for EBITDA: up 739.1% in 2022, down 469.11% in 2022.
  • Tracing VIR's EBITDA over 5 years: stood at $571.8 million in 2021, then tumbled by 126.32% to -$150.5 million in 2022, then grew by 7.63% to -$139.0 million in 2023, then increased by 15.73% to -$117.2 million in 2024, then skyrocketed by 59.09% to -$47.9 million in 2025.
  • Business Quant data shows EBITDA for VIR at -$47.9 million in Q4 2025, -$173.4 million in Q3 2025, and -$118.4 million in Q2 2025.